787633-69-6

Upstream product

• 2420-26-0 4-chlorosalicylaldehyde 
• 106-95-6 allyl bromide 
• 93856-97-4 allyl 2-(allyloxy)-4-chlorobenzoate 
• 900504-98-5 (2-(allyloxy)-4-chlorophenyl)methanol 
• 64917-81-3 4-chloro-2-hydroxybenzyl alcohol 
• 5106-98-9 4-chlorosalicylic acid 

Downstream Products

• 900504-98-5 (2-(allyloxy)-4-chlorophenyl)methanol 
• 900505-04-6 4-(2-allyloxy-4-chloro-benzyl)-3-(4-chloro-phenyl)-7-iodo-1-[2-(2-methoxy-ethoxy)-ethyl]-3,4-dihydro-1H-benzo[e][1,4]diazepine-2,5-dione 
• 900504-99-6 2-allyloxy-4-chloro-1-chloromethylbenzene 

Relevant academic research and scientific papers

Synthesis of chroman-4-one and indanone derivatives via silver catalyzed radical ring opening/coupling/cyclization cascade

A variety of chroman-4-one and indanone derivatives were conveniently synthesized from readily available cyclopropanols and alkenyl aldehydes via a silver catalyzed radical ring-opening/coupling/cyclization cascade. The reaction proceeded under mild and neutral conditions with broad substrate scope and afforded the desired products in moderate to good yields. A probable mechanism for the cascade reaction was also proposed.

Silver-Catalyzed Radical Cascade Cyclization toward 1,5-/1,3-Dicarbonyl Heterocycles: An Atom-/Step-Economical Strategy Leading to Chromenopyridines and Isoxazole-/Pyrazole-Containing Chroman-4-Ones

A novel and convenient silver-catalyzed radical cascade cyclization toward a large variety of 1,5-/1,3-dicarbonyl heterocycles containing a chroman-4-one, indanone, or 2,3-dihydroquinolin-4(1H)-one moiety was developed, by reacting various 2-functionalized benzaldehydes, including 2-allyloxy benzaldehydes, 2-allyl benzaldehyde, and 2-N(Ts)CH2-CH CH2 substituted benzaldehyde, with 1,3-dicarbonyl compounds in the presence of AgNO3/K2S2O8 in one pot under mild reaction conditions. The newly obtained 1,5-/1,3-dicarbonyl-containing heterocycles were further used directly to synthesize more structurally diverse polyheterocycles, mainly including chromenopyridines as well as isoxazole- or pyrazole-containing chroman-4-ones.

Cycloisomerization between Aryl Enol Ether and Silylalkynes under Ruthenium Hydride Catalysis: Synthesis of 2,3-Disubstituted Benzofurans

Metal-catalyzed cycloisomerization reactions of 1,n-enynes have become conceptually and chemically attractive processes in the search for atom economy, which is a key subject of current research. However, metal-catalyzed cycloisomerization between aryl enol ether and silylalkynes has not been developed. The ruthenium hydride complex catalyzed cycloisomerization between aryl enol ether and silylalkynes is reported to give benzofurans having useful functional groups, vinyl and trimethylsilylmethyl, on the 2- and 3-positions, respectively.

The Synthesis of 5-Amino-dihydrobenzo[b]oxepines and 5-Amino-dihydrobenzo[b]azepines via Ichikawa Rearrangement and Ring-Closing Metathesis

The combination of Ichikawa's rearrangement and a ring-closing metathesis reaction of allyl carbamates is presented as a method for the preparation of 5-amino-substituted 2,5-dihydro-benzo[b]oxepines, 2,5-dihydro-benzo[b]azepines, and 2,5-dihydro-benzo[b]thiepins. It was demonstrated that the use of nonracemic allyl carbamates enables the synthesis of enantioenriched benzo-fused seven-membered heterocycles. Finally, it was shown that further functionalization of the obtained structures allows access to pharmacologically active 5-amino-substituted 2,3,4,5-tetrahydro-1-benzo[b]oxepine scaffolds.

One-pot synthesis of 5-amino-2,5-dihydro-1-benzoxepines: Access to pharmacologically active heterocyclic scaffolds

A one-pot multibond-forming process involving a thermally mediated Overman rearrangement and a ring closing metathesis reaction of allylic trichloroacetimidates bearing a 2-allyloxyaryl group has been developed for the synthesis of 5-amino-substituted 2,5-dihydro-1-benzoxepines. Chemoselective reduction and functionalization of these compounds allowed access to a range of pharmacologically active 5-amino-2,3,4,5-tetrahydro-1-benzoxepine scaffolds.

Gold-catalyzed rearrangement of allylic oxonium ylides: Efficient synthesis of highly functionalized dihydrofuran-3-ones

"Diazo" not needed: The title reaction results in the rearrangement of oxonium ylides, which were prepared from readily available homopropargylic allylic ethers instead of diazo compounds, through two different mechanisms: a concerted 2,3-sigmatropic rearrangement, or a stepwise 1,4-allyl migration followed by a Claisen rearrangement (see scheme). Copyright

Copper catalyzed selective oxidation of benzyl alcohol to benzaldehyde

Selective oxidation of benzyl alcohols was observed in presence of allyl,-CH3 and phenolic-OH group. The reaction of primary benzylic alcohols was very clean using 2 moles of copper chloride in THF for 2 hrs at 80°C . The only product identified was benzaldehydes. It was observed that the reaction times for electron releasing arenes were significantly shorter. The reaction time for o-hydroxybenzaldehydes required longer reaction time which might be attributed to co-ordination of the phenolic OH group with copper chlorides. Secondary benzylic alcohols gave very clean and high yield of ketones for example the oxidation benzoin required only half an hour to reach completion with 100% yield. Similarly 2'-allyloxybenzyl alcohols undergo oxidation reaction to gave high yields of 2'-allyloxybenzaldehyde without any change in allyl group like deallylation, isomerization and addition to alkene bond.

CARBOXAMIDE DERIVATIVES AS MUSCARINIC RECEPTOR ANTAGONISTS

The invention relates to compounds of Formula (I) processes and intermediates for their preparation, their use as muscarinic antagonists and pharmaceutical composition containing them.

Novel 1,4-benzodiazepine-2,5-diones as Hdm2 antagonists with improved cellular activity

The disruption of the p53-Hdm2 protein-protein interaction induces cell growth arrest and apoptosis. We have identified the 1,4-benzodiazepine-2,5-dione scaffold as a suitable template for inhibiting this interaction by binding to the Hdm2 protein. Several compounds have been made with improved potency, solubility, and cell-based activities.

Combinational therapy involving a small molecule inhibitor of the MDM2: P53 interaction

The present invention is directed to a combinational therapy for treating cancer or other cell proliferative diseases. Such a therapy combines the use of radiation therapy or chemotherapy with the use of a small molecule inhibitor of the MDM2: p53 interaction.